Friday, the European Medicines Agency’s Committee for Medicinal Products for Human Use recommended against a conditional marketing nod for Roche and Sarepta’s gene therapy Elevidys in ambulatory DMD patients. More: Roche won't throw in the towel after DMD gene therapy
read moreAlthough Sarepta Therapeutics managed to defuse a brief stalemate with the FDA earlier this week, the U.S. drug regulator is reportedly going to put the company to work in order to affirm the safety of its Duchenne muscular dystrophy gene
read moreA soon-to-be-released documentary aims to change the conversation around hemophilia, where many female patients go misdiagnosed for years and often feel ignored or overlooked by healthcare providers. More: Sanofi lends support to ‘Dismissed’ film about 5 women’s experiences with hemophilia
read moreA direct-to-consumer program for its drugs could bring down higher U.S. drug prices while cutting out pharmacy benefit managers. More: Roche CEO weighs direct-to-consumer drug sales to ease US drug pricing woes, cut out middlemen Source: fierce
read moreJust as new outbreaks of chikungunya threaten to become another epidemic, Bavarian Nordic, maker of a vaccine against the mosquito-borne virus, has entered discussions of a potential buyout. More: Bavarian Nordic confirms buyout talks with private equity firms amid new
read moreWith tariffs looming and pricing policies shifting, life sciences companies may be on the cusp of a “pivotal moment,” according to Deloitte. More: Tariffs, pricing policy changes bring industry to a 'pivotal moment': Deloitte survey Source: fierce
read more© 1994 - 2025 B.M. Pharmaceuticals